Lantern Pharma Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $29.9M
- Price
- $2.34
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.18%
- Volume
- 185.1K
About
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Quick stats
Shares outstanding12.8M
Computed float7.3M
Float / shares56.7%
Cash runway (months)0.5
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001763950
AI Summary
AI-generated1/45
standardbullishearnings
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Lantern Pharma reported Q2 2026 financial results, highlighting a 25% year-over-year decrease in operating loss to $3.5 million and a cash position of $7.4 million as of June 30.
Operationally, the company announced that Open Medicine AI (OMAI) has been established as a separate, wholly-owned subsidiary with executed commercial licensing agreements, while the FDA reviewed LP-300 protocol amendments without objection.
Clinical updates include deepening progression-free survival data for LP-300 in the HARMONIC trial and EMA clearance for an investigator-initiated Phase 1b/2 trial of LP-184 in bladder cancer.
Red flags
- cash balance of $7.4M is low for a clinical-stage biotech with multiple ongoing trials
- net loss widened to $7.1M due to non-cash warrant expense driven by stock price increase
- company intends to pursue additional capital raises to extend runway